Innovent Biologics Expands Access to Treatments with Inclusion in China's National Reimbursement Drug List

Innovent Biologics, renowned for its innovative biopharmaceuticals, has announced a pivotal update that will enhance patient access to treatments in China. Recently, the company confirmed that its product SINTBILO® has been included in the updated National Reimbursement Drug List (NRDL), marking a significant development for the treatment of hypercholesterolemia. Alongside this, a new indication for olverembatinib, a BCR-ABL inhibitor, has also gained entry into the NRDL, offering expanded treatment options for patients suffering from chronic myeloid leukemia (CML).

Introduction of SINTBILO®

As of January 1, 2025, SINTBILO® (tafolecimab injection), an anti-PCSK9 monoclonal antibody, will be available in the NRDL for the treatment of adult patients afflicted by primary hypercholesterolemia, which includes both familial and non-familial types, as well as mixed dyslipidemia. This marks a major milestone as SINTBILO® represents Innovent’s foray into the cardiovascular sector. The drug offers multiple dosing regimens — 150mg every two weeks, 450mg every four weeks, and 600mg every six weeks — and has been shown to significantly lower low-density lipoprotein cholesterol (LDL-C) levels by nearly 70% and lipoprotein (a) by approximately 50%. The introduction of SINTBILO® to the NRDL is a substantial advancement in cholesterol management for patients across China, potentially improving the quality of life for many.

Olverembatinib's New Indication

In addition, the newly included indication for olverembatinib in the NRDL signifies another step forward in the treatment landscape for CML patients. The coverage now includes therapy for those with chronic-phase and accelerated-phase CML who have the T315I mutation, as well as for patients resistant or intolerant to first and second-generation tyrosine kinase inhibitors (TKIs). Olverembatinib is notable as the first third-generation BCR-ABL inhibitor approved by the National Medical Products Administration in China, showcasing Innovent's commitment to addressing critical healthcare needs in the oncology field.

Dr. Michael Yu, founder and CEO of Innovent, expressed optimism regarding these advancements, highlighting the potential to make innovative therapies more accessible and affordable for patients. He stated, "The inclusion of SINTBILO® in the NRDL will significantly improve the availability of this innovative therapy to patients with hypercholesterolemia in China. Additionally, with the new indication for olverembatinib, we expect to cater to a wider range of CML patients."

Innovent's Commitment to Patients

This announcement aligns with Innovent's mission to empower patients with affordable biopharmaceutical solutions. The company has maintained a focused investment in pioneering new treatments across various therapeutic areas, including oncology, cardiovascular, metabolic, autoimmune, and ophthalmological diseases. Innovent's approach emphasizes enhancing drug affordability and access to ensure the benefits of high-quality medicines are extended to those in need.

In total, Innovent has launched 11 different products and has an additional 5 drug applications currently under regulatory review, along with a robust pipeline of clinical trials advancing various novel molecules.

Conclusion

The updates made to the NRDL represent a proactive step in addressing important healthcare challenges in China, demonstrating Innovent's commitment to improving patient care and reinforcing its position as a leader in the biopharmaceutical industry. By continuously innovating and expanding treatment options, Innovent not only focuses on patient needs but also contributes significantly to the advancements in public health outcomes across China and beyond.

For more insights and updates on Innovent Biologics, visit their official website or follow them on social media channels.